Valuation: Jade Biosciences, Inc.

Market Cap 1.29B 1.14B 1.05B 975M 1.84B 123B 1.88B 12.58B 4.88B 60.42B 4.86B 4.76B 210B P/E 2026 *
-8.38x
P/E 2027 * -8.46x
Enterprise Value 1.04B 914M 841M 784M 1.48B 98.98B 1.51B 10.12B 3.92B 48.59B 3.91B 3.82B 169B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jade Biosciences, Inc.

1 day-6.53%
1 week-6.83%
Current month-8.55%
1 month+14.48%
3 months+31.18%
6 months+43.50%
Current year+31.69%
1 week 20.27
Extreme 20.27
23.12
1 month 14.28
Extreme 14.28
23.49
Current year 12.45
Extreme 12.45
28
1 year 6.67
Extreme 6.67
28
3 years 6.56
Extreme 6.565
28
5 years 6.56
Extreme 6.565
28
10 years 6.56
Extreme 6.565
28
Manager TitleAgeSince
Chief Executive Officer 50 2025-04-27
Director of Finance/CFO 38 2025-07-13
Chief Tech/Sci/R&D Officer 53 2026-04-21
Director TitleAgeSince
Director/Board Member 50 2025-04-27
Director/Board Member 42 2025-04-27
Chairman 57 2025-04-27
Date Insider Type Main position Quantity % Market Cap.
06-24Free

Director

47,675 0.0966%
06-08Free

Chairman

34,843 0.0706%
06-08
Fairmount Funds Management LLC
FreeCompany 34,843 0.0706%
Change 5-day change 1-year change 3-year change Capi.($)
-6.53%-6.83%+88.15% - 1.29B
+0.69%+5.44%+1.36%+6.99% 48.62B
-0.20%+4.29%+399.62%+592.55% 39.86B
+1.87%+10.63%+25.27%-6.70% 33.91B
+2.72%+8.36%+22.12%+64.98% 32.32B
+1.20%+2.26%+15.60%+32.43% 24.73B
+0.64%+2.67% - - 16.63B
+2.80%+7.09%+70.78%+132.94% 15.52B
+0.99%+1.26%+13.98%+18.72% 13.63B
-0.20%+7.43%+14.65%-28.85% 13.41B
Average +0.38%+6.87%+72.39%+101.63% 23.99B
Weighted average by Cap. +1.09%+7.68%+87.57%+128.68%

Financials

2026 *2027 *
Net sales - -
Net income -173M -152M -140M -130M -246M -16.47B -251M -1.68B -652M -8.08B -650M -636M -28.13B -191M -168M -155M -144M -272M -18.18B -277M -1.86B -720M -8.92B -718M -702M -31.05B
Net Debt -254M -223M -205M -191M -360M -24.1B -367M -2.46B -955M -11.83B -952M -931M -41.18B -300M -264M -243M -226M -426M -28.55B -435M -2.92B -1.13B -14.01B -1.13B -1.1B -48.77B
Logo Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Employees
55
Date Price Change Volume
26-07-02 US$20.32 -6.85% 372,028
26-07-01 US$21.81 -1.85% 861,567
26-06-30 US$22.22 +0.50% 893,408
26-06-29 US$22.11 +0.50% 1,122,561
26-06-26 US$22.00 +0.87% 2,664,341
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
21.81USD
Average target price
48.50USD
Spread / Average Target
+122.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JBIO Stock